NCT06051760View on ClinicalTrials.gov

NV-001 in the Treatment of Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

June 1, 2025

Conditions
Malignant Neoplasm
Interventions
BIOLOGICAL

NV-001

NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.

Trial Locations (1)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER